{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:35:30Z","timestamp":1791279330244,"version":"4.1.0"},"reference-count":102,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1185\/03007995.2013.818531","type":"journal-article","created":{"date-parts":[[2013,6,24]],"date-time":"2013-06-24T04:46:31Z","timestamp":1372049191000},"page":"1147-1160","source":"Crossref","is-referenced-by-count":46,"title":["What do we know about the safety of corticosteroids in rheumatoid arthritis?"],"prefix":"10.1185","volume":"29","author":[{"given":"Olivier","family":"Ethgen","sequence":"first","affiliation":[{"name":"Department of Public Health Sciences, Epidemiology and Health Economics, University of Li\u00e8ge","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"de Lemos Esteves","sequence":"additional","affiliation":[{"name":"Life Sciences Library, University of Li\u00e8ge","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bruyere","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Epidemiology and Health Economics, University of Li\u00e8ge","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Epidemiology and Health Economics, University of Li\u00e8ge","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2013,7,3]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202021"},{"key":"e_1_3_2_3_1","first-page":"1","article-title":"The use of low-dose prednisone in the management of rheumatoid arthritis","volume":"50","author":"Lim SS","year":"2001","unstructured":"Lim SS, Conn DL. The use of low-dose prednisone in the management of rheumatoid arthritis. Bull Rheum Dis 2001;50:1-4","journal-title":"Bull Rheum Dis"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(05)70208-8"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200110)45:5<468::AID-ART367>3.0.CO;2-A"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-002-0068-z"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-136-1-200201010-00013"},{"key":"e_1_3_2_8_1","first-page":"S77","article-title":"Glucocorticoid use in rheumatoid arthritis: benefits, mechanisms, and risks","volume":"22","author":"Townsend HB","year":"2004","unstructured":"Townsend HB, Saag KG. Glucocorticoid use in rheumatoid arthritis: benefits, mechanisms, and risks. Clin Exp Rheumatol 2004;22:S77-82","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_2_9_1","first-page":"S186","article-title":"Low dose glucocorticoids in early rheumatoid arthritis","volume":"21","author":"Strand V","year":"2003","unstructured":"Strand V, Simon LS. Low dose glucocorticoids in early rheumatoid arthritis. Clin Exp Rheumatol 2003;21:S186-90","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2003.10.002"},{"key":"e_1_3_2_11_1","first-page":"S59","article-title":"Glucocorticoids in rheumatoid arthritis: lessons from the Utrecht study","volume":"29","author":"Jacobs JW","year":"2011","unstructured":"Jacobs JW, Bijlsma JW. Glucocorticoids in rheumatoid arthritis: lessons from the Utrecht study. Clin Exp Rheumatol 2011;29:S59-62","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_2_12_1","first-page":"S130","article-title":"Long-term prednisone in doses of less than 5\u2009mg\/day for treatment of rheumatoid arthritis: personal experience over 25 years","volume":"29","author":"Pincus T","year":"2011","unstructured":"Pincus T, Castrejon I, Sokka T. Long-term prednisone in doses of less than 5\u2009mg\/day for treatment of rheumatoid arthritis: personal experience over 25 years. Clin Exp Rheumatol 2011;29:S130-8","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-136-1-200201010-00006"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.008573"},{"key":"e_1_3_2_15_1","first-page":"S73","article-title":"The clinical efficacy of 3\u2009mg\/day prednisone in patients with rheumatoid arthritis: evidence from a randomized, double-blind, placebo-controlled withdrawal clinical trial","volume":"29","author":"Pincus T","year":"2011","unstructured":"Pincus T. The clinical efficacy of 3\u2009mg\/day prednisone in patients with rheumatoid arthritis: evidence from a randomized, double-blind, placebo-controlled withdrawal clinical trial. Clin Exp Rheumatol 2011;29:S73-6","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21298"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21421"},{"key":"e_1_3_2_18_1","first-page":"S68","article-title":"A dose of only 5\u2009mg prednisolone daily retards radiographic progression in early rheumatoid arthritis \u2013 the Low-Dose Prednisolone Trial","volume":"29","author":"Wassenberg S","year":"2011","unstructured":"Wassenberg S, Rau R, Zeidler H; Low-Dose Prednisolone Trial G. A dose of only 5\u2009mg prednisolone daily retards radiographic progression in early rheumatoid arthritis \u2013 the Low-Dose Prednisolone Trial. Clin Exp Rheumatol 2011;29:S68-72","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-5-201203060-00004"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200305000-00004"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.05342.x"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.179"},{"key":"e_1_3_2_23_1","first-page":"2582","article-title":"A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis","volume":"27","author":"Sinigaglia L","year":"2000","unstructured":"Sinigaglia L, Nervetti A, Mela Q, et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol 2000;27:2582-9","journal-title":"J Rheumatol"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.12.1375"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200106)44:6<1254::AID-ART216>3.0.CO;2-G"},{"key":"e_1_3_2_26_1","first-page":"508","article-title":"Loss of cortical bone from the metacarpal diaphysis in patients with rheumatoid arthritis: independent effects of systemic inflammation and glucocorticoids","volume":"33","author":"Roldan JF","year":"2006","unstructured":"Roldan JF, Del Rincon I, Escalante A. Loss of cortical bone from the metacarpal diaphysis in patients with rheumatoid arthritis: independent effects of systemic inflammation and glucocorticoids. J Rheumatol 2006;33:508-16","journal-title":"J Rheumatol"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22117"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-008-0576-x"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/13603124.2011.605475"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20661"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22418"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem311"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23811"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100979"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.057265"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23913"},{"key":"e_1_3_2_37_1","first-page":"387","article-title":"The risk of hospitalized infection in patients with rheumatoid arthritis","volume":"35","author":"Smitten AL","year":"2008","unstructured":"Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008;35:387-93","journal-title":"J Rheumatol"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200702"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.144741"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel328"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23112"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24476"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/003693300404900407"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.048934"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30107"},{"key":"e_1_3_2_46_1","first-page":"1832","article-title":"Acute lower respiratory tract infections in patients with rheumatoid arthritis","volume":"34","author":"Coyne P","year":"2007","unstructured":"Coyne P, Hamilton J, Heycock C, et al. Acute lower respiratory tract infections in patients with rheumatoid arthritis. J Rheumatol 2007;34:1832-6","journal-title":"J Rheumatol"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092163"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.100008"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep096"},{"key":"e_1_3_2_50_1","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2310\/JIM.0b013e31818e82d7","article-title":"Effects of low-dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis: a meta-analysis","volume":"56","author":"Lee YH","year":"2008","unstructured":"Lee YH, Woo JH, Choi SJ, et al. Effects of low-dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis: a meta-analysis. J Investig Med 2008;56:1011-18","journal-title":"J Investig Med"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.02.009"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3453"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.02.040"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg355"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.114579"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.070771"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-2059-4"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200828030-00002"},{"key":"e_1_3_2_59_1","first-page":"407","article-title":"Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results","volume":"35","author":"Morishita M","year":"2008","unstructured":"Morishita M, Nagashima M, Wauke K, et al. Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. J Rheumatol 2008;35:407-13","journal-title":"J Rheumatol"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.062570"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200623100-00001"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.135061"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2011.07.003"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10613"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.4.350"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-005-2016-z"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.rhu.0000242778.65766.22"},{"key":"e_1_3_2_68_1","first-page":"61","article-title":"Screening and treatment of glucocorticoid-induced osteoporosis in rheumatoid arthritis patients in an urban multispecialty practice","volume":"15","author":"Ledwich LJ","year":"2009","unstructured":"Ledwich LJ, Clarke K. Screening and treatment of glucocorticoid-induced osteoporosis in rheumatoid arthritis patients in an urban multispecialty practice. J 2009;15:61-4","journal-title":"J"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-010-1201-x"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes079"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s007740070008"},{"key":"e_1_3_2_72_1","first-page":"102","article-title":"Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins","volume":"25","author":"Gazi IF","year":"2007","unstructured":"Gazi IF, Boumpas DT, Mikhailidis DP, et al. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheumatol 2007;25:102-11","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken159"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.10-4-326"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573212700124103971"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes305"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.1.61"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-003-0294-3"},{"key":"e_1_3_2_79_1","first-page":"2475","article-title":"The effect of corticosteroid medication on quantitative MR parameters of the brain","volume":"26","author":"Steens SC","year":"2005","unstructured":"Steens SC, Steup-Beekman GM, Bosma GP, et al. The effect of corticosteroid medication on quantitative MR parameters of the brain. Am J Neuroradiol 2005;26:2475-80","journal-title":"Am J Neuroradiol"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009740601153774"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4893-07.2008"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2578"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.096925"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel396"},{"key":"e_1_3_2_85_1","first-page":"73","article-title":"Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial","volume":"28","author":"Karstila KL","year":"2010","unstructured":"Karstila KL, Rantalaiho VM, Mustonen JT, et al. Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial. Clin Exp Rheumatol 2010;28:73-8","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.140210"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2009.02.007"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1080\/17453670810016641"},{"key":"e_1_3_2_89_1","first-page":"19","article-title":"What about prednisone? It might be the missing ingredient in the ACR recommendations on the treatment of RA","volume":"7","author":"Kirwan J","year":"2013","unstructured":"Kirwan J. What about prednisone? It might be the missing ingredient in the ACR recommendations on the treatment of RA. The Rheumatologist 2013;7:19","journal-title":"The Rheumatologist"},{"key":"e_1_3_2_90_1","first-page":"20","article-title":"The steroid question: is prednisone 3\u2009mg\/day an appropriate initial and long-term dose for patients with rheumatoid arthritis?","volume":"7","author":"Pincus T","year":"2013","unstructured":"Pincus T. The steroid question: is prednisone 3\u2009mg\/day an appropriate initial and long-term dose for patients with rheumatoid arthritis? The Rheumatologist 2013;7:20-3","journal-title":"The Rheumatologist"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21899"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3280d6471a"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32805e87d0"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2004.10.003"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2012.166"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2010.02.001"},{"issue":"4","key":"e_1_3_2_97_1","first-page":"iv27","article-title":"Lessons for the use of non-biologic anchor treatments for rheumatoid arthritis in the era of biologic therapies","volume":"51","author":"Jacobs JW","year":"2012","unstructured":"Jacobs JW. Lessons for the use of non-biologic anchor treatments for rheumatoid arthritis in the era of biologic therapies. Rheumatology (Oxford) 2012;51(Suppl 4):iv27-33","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_3_2_98_1","first-page":"123","article-title":"Chronotherapy with modified-release prednisone in patients with rheumatoid arthritis","volume":"8","author":"Alten R","year":"2012","unstructured":"Alten R. Chronotherapy with modified-release prednisone in patients with rheumatoid arthritis. Expert Rev 2012;8:123-33","journal-title":"Expert Rev"},{"key":"e_1_3_2_99_1","first-page":"159","article-title":"Efficacy, safety and mechanism of action of modified-release prednisone in rheumatoid arthritis","volume":"4","author":"Clarke L","year":"2012","unstructured":"Clarke L, Kirwan J. Efficacy, safety and mechanism of action of modified-release prednisone in rheumatoid arthritis. Ther 2012;4:159-66","journal-title":"Ther"},{"key":"e_1_3_2_100_1","first-page":"S42","article-title":"Prednisone chronotherapy","volume":"29","author":"Spies CM","year":"2011","unstructured":"Spies CM, Cutolo M, Straub RH, et al. Prednisone chronotherapy. Clin Exp Rheumatol 2011;29:S42-5","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.126888"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes085"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh594"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/03007995.2013.818531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:41:11Z","timestamp":1772746871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/03007995.2013.818531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,3]]},"references-count":102,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1185\/03007995.2013.818531"],"URL":"https:\/\/doi.org\/10.1185\/03007995.2013.818531","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,3]]}}}